635 related articles for article (PubMed ID: 1836471)
1. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
3. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
Liu JN; Gurewich V
Blood; 1993 Feb; 81(4):980-7. PubMed ID: 8428004
[TBL] [Abstract][Full Text] [Related]
5. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
9. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK.
Liu JN; Gurewich V
Biochemistry; 1992 Jul; 31(27):6311-7. PubMed ID: 1385727
[TBL] [Abstract][Full Text] [Related]
10. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
12. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
[TBL] [Abstract][Full Text] [Related]
13. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
14. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.
López-Alemany R; Longstaff C; Hawley S; Mirshahi M; Fábregas P; Jardí M; Merton E; Miles LA; Félez J
Am J Hematol; 2003 Apr; 72(4):234-42. PubMed ID: 12666133
[TBL] [Abstract][Full Text] [Related]
16. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
Lind SE; Smith CJ
Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
[TBL] [Abstract][Full Text] [Related]
17. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
Lijnen HR; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activation by tissue plasminogen activator in the presence of stimulating CNBr fragment FCB-2 of fibrinogen is a two-phase reaction. Kinetic analysis of the initial phase of slow plasmin formation.
Beckmann R; Geiger M; Binder BR
J Biol Chem; 1988 May; 263(15):7176-80. PubMed ID: 2966802
[TBL] [Abstract][Full Text] [Related]
19. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen.
Grailhe P; Nieuwenhuizen W; Anglés-Cano E
Eur J Biochem; 1994 Feb; 219(3):961-7. PubMed ID: 8112348
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]